OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Albertsmeier on Radiotherapy Improving the Local Control of Sarcoma

March 17th 2017

Markus Albertsmeier, MD, surgeon, Ludwig Maximilian University of Munich, discusses radiotherapy improving the local control for patients with sarcoma.

Dr. O'Neil on Stemness Inhibitors for CRC Treatment

March 17th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of Medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the potential for stemness inhibitors as a treatment for patients with metastatic colorectal cancer (mCRC).

Dr. Bendell on Exciting Advancements in the Field of HCC

March 16th 2017

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses exciting research and advancements in the field of hepatocellular carcinoma.

Dr. Koyfman on IMRT and SBRT Reirradiation for Head and Neck Cancer

March 16th 2017

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) reirradiation for patients with head and neck cancer.

Dr. Moore on the NOVA Trial for Ovarian Cancer

March 16th 2017

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.

Dr. Gordon on Next Steps With Immunotherapy Research in Osteosarcoma

March 15th 2017

Nancy B. Gordon, MD, assistant professor, Department of Pediatrics, The University of Texas MD Anderson Center, discusses next steps for immunotherapy research in the field of osteosarcoma.

Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma

March 15th 2017

David J. Straus, MD, internist and hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) as a treatment for patients with Hodgkin lymphoma.

Dr. Goy on BR Plus Bortezomib for MCL Treatment

March 15th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of bendamustine and rituximab (Rituxan; BR) plus bortezomib (Velcade) as a potential treatment for patients with mantle cell lymphoma (MCL).

Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer

March 14th 2017

Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the FDA approval of ribociclib (LEE011) for use in combination with letrozole as a frontline therapy for patients with hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

Dr. Ahn on Neoadjuvant Treatments for Patients With Gastric Cancer

March 13th 2017

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses advances in neoadjuvant therapies for patients with gastric cancer during the 2017 OncLive State of the Science Summit on Gastrointestinal Malignancies.

Dr. McDermott Discusses the Future of Immune Checkpoints in RCC

March 13th 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the future of immunotherapies in the treatment of patients with kidney cancer.

Dr. Araujo on Emerging Data on Radium-223 for Patients With mCRPC

March 13th 2017

John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging data with radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.

Dr. Al-Batran on Future of Treatment in Gastric Cancer

March 11th 2017

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.

Dr. Jonasch on Alternative Sunitinib Scheduling for mRCC

March 11th 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).

Dr. Klein on Gene Mutations in Prostate Cancer

March 11th 2017

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses gene mutations in patients with prostate cancer.

Dr. Siefker-Radtke on PD-L1 as a Biomarker in Bladder Cancer

March 10th 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses why researchers and physicians should reconsider the utility of PD-L1 as a biomarker for patients with bladder cancer.

Dr. Choi on Evolution of RT in Prostate Cancer

March 10th 2017

Seungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical Medical Director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses how radiation therapy has evolved for the treatment of patients with prostate cancer.

Dr. Gomella on Challenges Facing Genetic Testing in Prostate Cancer

March 10th 2017

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses challenges facing genetic testing for patients with prostate cancer.

Dr. Linehan on Gene Mutations in Papillary Kidney Cancer

March 10th 2017

W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses gene mutations in papillary kidney cancer.

Dr. Corn on Sequencing Agents for Patients With mCRPC

March 10th 2017

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the agents available to treat patients with metastatic castration-resistant prostate cancer (mCRPC)